ISEE

AirClass 1-on-1 Further Upgrades Its Digital Smart Class

Tuesday, September 14, 2021 - 7:19am

Sources say that AirClass has built a brilliantly intelligent teaching system to enable AI interactive teaching.

Key Points: 
  • Sources say that AirClass has built a brilliantly intelligent teaching system to enable AI interactive teaching.
  • AirClass ( www.air-class.com ) is a global educational institution focused on one-on-one online tutoring, with over 500,000 paid students in total.
  • And the admission rate of teachers into AirClass is only 7.8% after various levels of strict checks and screening.
  • 91% of the students having studied with AirClass for over three months have seen significant improvement in their academic performance.

Iveric Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Friday, September 10, 2021 - 9:05pm

IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, M.D., President, will present an overview of the Company at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually from September 13-15, 2021.

Key Points: 
  • IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, M.D., President, will present an overview of the Company at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually from September 13-15, 2021.
  • ET and can be accessed on the Investor / Events & Presentations section of the Iveric Bio website at www.ivericbio.com .
  • Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs.
  • While Iveric Bio may elect to update these forward-looking statements at some point in the future, Iveric Bio specifically disclaims any obligation to do so unless required by law.

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thursday, September 2, 2021 - 1:00pm

IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on September 1, 2021, the Company granted equity-based awards pursuant to the Companys 2019 Inducement Stock Incentive Plan to three newly-hired, non-executive employees.

Key Points: 
  • IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on September 1, 2021, the Company granted equity-based awards pursuant to the Companys 2019 Inducement Stock Incentive Plan to three newly-hired, non-executive employees.
  • The inducement grants consisted of a non-statutory option to purchase an aggregate of 155,000 shares of the Companys common stock, and two grants of an aggregate of 12,500 restricted stock units for shares of the Companys common stock.
  • The inducement grants are subject to the terms and conditions of award agreements covering the grants and the Companys 2019 Inducement Stock Incentive Plan.
  • Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs.

Iveric Bio to Present at the H.C. Wainwright Ophthalmology Virtual Conference

Tuesday, August 10, 2021 - 1:00pm

IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, M.D., President, will present an overview of the Company at the H.C. Wainwright Ophthalmology Virtual Conference on Tuesday, August 17, 2021.

Key Points: 
  • IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, M.D., President, will present an overview of the Company at the H.C. Wainwright Ophthalmology Virtual Conference on Tuesday, August 17, 2021.
  • Investors and the general public are invited to listen to both the on-demand and live webcasts on the Investor / Events & Presentations section of the Iveric Bio website at www.ivericbio.com .
  • Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs.
  • While Iveric Bio may elect to update these forward-looking statements at some point in the future, Iveric Bio specifically disclaims any obligation to do so unless required by law.

Iveric Bio to Participate in the 2021 Wedbush PacGrow Healthcare Virtual Conference on August 11, 2021

Wednesday, August 4, 2021 - 9:05pm

IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, M.D., President, will participate in the panel discussion, Only Have Eyes For You - Ophthalmic Gene Therapy, at the 2021 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 11 at 8:00 a.m. Eastern Time.

Key Points: 
  • IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, M.D., President, will participate in the panel discussion, Only Have Eyes For You - Ophthalmic Gene Therapy, at the 2021 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 11 at 8:00 a.m. Eastern Time.
  • Investors and the general public are invited to listen to a live webcast on the Investor / Events & Presentations section of the Iveric Bio website at www.ivericbio.com .
  • Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs.
  • While Iveric Bio may elect to update these forward-looking statements at some point in the future, Iveric Bio specifically disclaims any obligation to do so.

Iveric Bio to Report Second Quarter 2021 Financial Results and Host Conference Call on Wednesday, August 4, 2021

Wednesday, July 28, 2021 - 1:00pm

IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its second quarter 2021 financial and operating results on Wednesday, August 4, 2021.

Key Points: 
  • IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its second quarter 2021 financial and operating results on Wednesday, August 4, 2021.
  • Following the announcement, the Iveric Bio management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Companys financial results and provide a general business update.
  • A live, listen-only audio webcast of the conference call can be accessed on the Investors section of the Iveric Bio website at www.ivericbio.com .
  • While Iveric Bio may elect to update these forward-looking statements at some point in the future, Iveric Bio specifically disclaims any obligation to do so.

ISEE Launches Autonomous Driving Solution for Yard Trucks to Optimize Logistics Hub and Warehouse Efficiency

Tuesday, June 8, 2021 - 5:14pm

ISEE today announced the launch of its groundbreaking AI-powered autonomous driving system to enhance performance and safety in transportation and logistics hubs.

Key Points: 
  • ISEE today announced the launch of its groundbreaking AI-powered autonomous driving system to enhance performance and safety in transportation and logistics hubs.
  • View the full release here: https://www.businesswire.com/news/home/20210608005929/en/
    ISEE announces the launch of its groundbreaking AI-powered autonomous driving system for yard trucks to enhance performance and safety in transportation and logistics hubs.
  • To learn more about ISEE and its autonomous driving solution, please visit www.isee.ai/ .
  • ISEE is an autonomous technology company that improves efficiency and safety with trucks designed to flexibly adapt to any environment and thrive alongside other workers.

David R. Guyer, MD to Step Down from Iveric Bio Board to Rejoin Venture Fund

Monday, April 5, 2021 - 11:45am

IVERIC bio, Inc. (Nasdaq: ISEE) today announced that David R. Guyer, MD, co-founder and Executive Chairman, is stepping down from the Iveric Bio Board after 14 years, effective following Iveric Bios 2021 Annual Stockholder Meeting scheduled to be held on May 19, 2021.

Key Points: 
  • IVERIC bio, Inc. (Nasdaq: ISEE) today announced that David R. Guyer, MD, co-founder and Executive Chairman, is stepping down from the Iveric Bio Board after 14 years, effective following Iveric Bios 2021 Annual Stockholder Meeting scheduled to be held on May 19, 2021.
  • Dr. Guyer will rejoin SV Health Investors as a Venture Partner having previously been both a Venture Partner and Partner at SV.
  • I will rejoin SV Health Investors where I will be able to focus on new company generation and board service.
  • Davids contributions to Iveric Bio have been significant, stated Axel Bolte, Member of the Board of Iveric Bio.

Iveric Bio to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Wednesday, March 3, 2021

Wednesday, February 24, 2021 - 1:00pm

IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its fourth quarter and full year 2020 financial and operating results on Wednesday, March 3, 2021.

Key Points: 
  • IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its fourth quarter and full year 2020 financial and operating results on Wednesday, March 3, 2021.
  • Following the announcement, the Iveric Bio management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Companys financial results and provide a general business update.
  • A live, listen-only audio webcast of the conference call can be accessed on the Investors section of the Iveric Bio website at www.ivericbio.com .
  • While Iveric Bio may elect to update these forward-looking statements at some point in the future, Iveric Bio specifically disclaims any obligation to do so.

IVERIC bio to Present at the 39th Annual J.P. Morgan Healthcare Conference

Thursday, December 17, 2020 - 1:00pm

IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer and President, will present an overview of the Company at the 39th Annual J.P. Morgan Healthcare Conference in a virtual session on Thursday, January 14, 2021 at 2:50 p.m. Eastern Time.

Key Points: 
  • IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer and President, will present an overview of the Company at the 39th Annual J.P. Morgan Healthcare Conference in a virtual session on Thursday, January 14, 2021 at 2:50 p.m. Eastern Time.
  • An archived replay of the webcast will be available on the Companys website immediately following the conference and for at least two weeks thereafter.
  • IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs.
  • While IVERIC bio may elect to update these forward-looking statements at some point in the future, IVERIC bio specifically disclaims any obligation to do so.